Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keverprazan Dual vs Quadruple Therapy for H. pylori Eradication
NCT06777732Phase 1Not yet recruiting
- Sponsor
- Nanjing First Hospital
- Start
- Mar 2025
- Primary completion
- Sep 2025
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of keverprazan in Helicobacter pylori infection (3 arms), sponsored by Nanjing First Hospital. Primary endpoint: Adverse event. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
keverprazan
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT06777732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06777732.